Inflammatory cytokines in cystic fibrosis lungs.

American Journal of Respiratory and Critical Care Medicine 152, 2111-2118

DOI: 10.1164/ajrccm.152.6.8520783

Citation Report

#	Article	IF	CITATIONS
1	Oxidative Stress in Cystic Fibrosis: Does It Occur and Does It Matter?. Advances in Pharmacology, 1996, 38, 491-513.	2.0	80
2	Inflammation in Cystic Fibrosis. Mediators of Inflammation, 1996, 5, 121-143.	3.0	0
3	L'inflammation dans la Mucoviscidose. Mediators of Inflammation, 1996, 5, 144-169.	3.0	1
4	Symposium session summaries. Pediatric Pulmonology, 1996, 22, 78-208.	2.0	0
5	Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clinical and Experimental Immunology, 1996, 106, 374-388.	2.6	80
6	Mechanisms of airway inflammation in cystic fibrosis. Pediatric Allergy and Immunology, 1996, 7, 63-66.	2.6	5
7	Cystic fibrosis and allergy. Pediatric Allergy and Immunology, 1996, 7, 67-69.	2.6	12
8	Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum American Journal of Respiratory and Critical Care Medicine, 1996, 154, 783-788.	5.6	26
9	Use of Bronchoalveolar Lavage Semiquantitative Cultures in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 286-291.	5.6	28
10	Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Archives of Disease in Childhood, 1997, 77, 124-130.	1.9	94
11	Increased Production of TNF-α May Play a Role in Osteoporosis in Cystic Fibrosis Patients. Chest, 1997, 112, 574.	0.8	11
12	Lower Airway Inflammation in Infants and Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1197-1204.	5.6	449
13	Increased Production of TNF-α May Play a Role in Osteoporosis in Cystic Fibrosis Patients. Chest, 1997, 112, 574.	0.8	0
14	The Changing Presentation of Lung Adenocarcinoma. Chest, 1997, 112, 573-574.	0.8	0
15	Genetic and Immunologic Aspects of Cystic Fibrosis. Annals of Allergy, Asthma and Immunology, 1997, 79, 379-394.	1.0	9
16	Correspondence. American Journal of Medicine, 1997, 103, 328-336.	1.5	2
18	Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology. Pediatric Pulmonology, 1997, 24, 137-142.	2.0	274
19	Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatric Pulmonology, 1997, 24, 173-177.	2.0	183

#	Article	IF	CITATIONS
20	Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis. European Journal of Human Genetics, 1998, 6, 12-31.	2.8	70
21	Effects of bronchopulmonary inflammation induced by Pseudomonas aeruginosa on adenovirus-mediated gene transfer to airway epithelial cells in mice. Gene Therapy, 1998, 5, 345-351.	4.5	47
22	Severe viral respiratory infections in infants with cystic fibrosis. Pediatric Pulmonology, 1998, 26, 371-379.	2.0	169
23	Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. , 1998, 184, 323-331.		159
24	Destruction and loss of bronchial cartilage in cystic fibrosis. Human Pathology, 1998, 29, 65-73.	2.0	34
25	The Bronchoalveolar Lavage Fluid of Cystic Fibrosis Lung Transplant Recipients Demonstrates Increased Interleukin-8 and Elastase and Decreased IL-10. Journal of Interferon and Cytokine Research, 1998, 18, 851-854.	1.2	32
26	Selective Up-Regulation of Chemokine IL-8 Expression in Cystic Fibrosis Bronchial Gland Cells in Vivo and in Vitro. American Journal of Pathology, 1998, 153, 921-930.	3.8	158
27	Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax, 1998, 53, 1018-1021.	5.6	128
28	Nitric oxide metabolites in cystic fibrosis lung disease. Archives of Disease in Childhood, 1998, 78, 49-53.	1.9	141
29	Overproduction of the CFTR R Domain Leads to Increased Levels of AsialoGM1 and IncreasedPseudomonas aeruginosaBinding by Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1998, 19, 269-277.	2.9	101
30	Generation of a Transgenic Mouse with Lung-specific Overexpression of the Human Interleukin-1 Receptor Antagonist Protein. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 429-434.	2.9	13
31	Neutrophil Elastase Promotes Rapid Exocytosis in Human Airway Gland Cells by Producing Cytosolic Ca ^{2 +} Oscillations. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 32-42.	2.9	19
32	Subepithelial Fibrosis and Degradation of the Bronchial Extracellular Matrix in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 580-588.	5.6	59
33	Neutrophil Adhesion Molecule Surface Expression and Responsiveness in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 756-761.	5.6	49
34	Circulating Adhesion Molecules in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1234-1239.	5.6	49
35	Role of CFTR in Airway Disease. Physiological Reviews, 1999, 79, S215-S255.	28.8	387
36	The protease-antiprotease battle in the cystic fibrosis lung. Journal of the Royal Society of Medicine, 1999, 92, 23-30.	2.0	27
37	Soluble Tumor Necrosis Factor (TNF) Receptors p55 and p75 and Interleukin-10 Downregulate TNF- α Activity during the Lung Response to Silica Particles in NMRI Mice. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 137-145.	2.9	29

	CITATION REPORT	
Article	IF	CITATIONS
IL-10 Attenuates Excessive Inflammation in Chronic <i>Pseudomonas</i> Infection in Mice. Americ Journal of Respiratory and Critical Care Medicine, 1999, 160, 2040-2047.	an 5.6	120
Tumor Necrosis Factor \hat{I}_{\pm} and Toxicology. Critical Reviews in Toxicology, 1999, 29, 491-511.	3.9	114
Proteinase 3, a Potent Secretagogue in Airways, Is Present in Cystic Fibrosis Sputum. American Jou of Respiratory Cell and Molecular Biology, 1999, 20, 729-736.	ırnal 2.9	115
Inflammation and CFTR: Might Neutrophils be the Key in Cystic Fibrosis?. Mediators of Inflammatic 1999, 8, 7-11.	on, 3.0	35
The pathogenic consequences of a single mutated CFTR gene. Thorax, 1999, 54, S19-S23.	5.6	31
Increased carbon monoxide in exhaled air of patients with cystic fibrosis. Thorax, 1999, 54, 917-92	20. 5.6	85
Effect of Pseudomonas aeruginosa exotoxin A on endotoxin-induced tumour necrosis factor production in murine lung. Journal of Medical Microbiology, 1999, 48, 471-477.	1.8	8
Detecting peripheral nerve involvement in rheumatoid arthritis patients: Comment on the article b Lanzillo et al. Arthritis and Rheumatism, 1999, 42, 1304-1304.	уу 6 . 7	2
Autoantibodies against bactericidal/permeability-increasing protein in cystic fibrosis patients: Comment on the article by Hoffman and Specks. Arthritis and Rheumatism, 1999, 42, 1305-1306.	6.7	3
Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance pneumococcal vaccination in patients with autosplenectomy: Comment on the article by Battafare et al. Arthritis and Rheumatism, 1999, 42, 1307-1308.	e of ano 6.7	19
Missense mutations in the cystic fibrosis gene in adult patients with asthma. Human Mutation, 19 510-519.	199, 14, 2.5	51
Immunological aspects of bronchopulmonary disease in cystic fibrosis. Pediatric Pulmonology, 199 27, 93-95.	99, 2.0	0
Increased cytokines and pamidronate-induced bone pain in adults with cystic fibrosis. Lancet, The, 353, 750.	1999, 13.7	10
Substituted Isoquinolines and Quinazolines as Potential Antiinflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor α. Journal of Medicinal Chemistry, 19942, 3860-3873.	99, 6.4	149
Altered respiratory epithelial cell cytokine production in cystic fibrosisâ~†â~†â~†â~†â~ Journal of Aller Clinical Immunology, 1999, 104, 72-78.	gy and 2.9	238
Genotype–phenotype correlations in cystic fibrosis: clinical severity of mutation S549R(T→G). E Respiratory Journal, 1999, 13, 103-106.	uropean 6.7	25

56	Expired hydrogen peroxide in breath condensate of cystic fibrosis patients. European Respiratory Journal, 1999, 13, 107-113.	6.7	51
57	Increased frequency of cystic fibrosis ΔF508 mutation in bronchiectasis associated with rheumatoid arthritis. European Respiratory Journal, 1999, 13, 1281-1287.	6.7	30

#

#	Article	IF	CITATIONS
58	Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease. European Respiratory Journal, 1999, 13, 1288-1292.	6.7	45
59	Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. European Respiratory Journal, 1999, 14, 339-346.	6.7	31
60	Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation. European Respiratory Journal, 1999, 14, 1136-1144.	6.7	76
61	Pitfall in the Use of Genotype Analysis as the Sole Diagnostic Criterion for Cystic Fibrosis. Pediatrics, 1999, 103, 823-826.	2.1	37
62	S100A8: emerging functions and regulation. Journal of Leukocyte Biology, 1999, 66, 549-556.	3.3	112
63	Reduced Interleukin-8 Production by Cystic Fibrosis Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 1073-1080.	2.9	30
64	The sialylation of bronchial mucins secreted by patients suffering from cystic fibrosis or from chronic bronchitis is related to the severity of airway infection. Glycobiology, 1999, 9, 311-321.	2.5	106
65	Chapter 6 The cystic fibrosis transmembrane conductance regulator in the gastrointestinal system. Current Topics in Membranes, 2000, 50, 187-248.	0.9	0
66	Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment. European Respiratory Journal, 2000, 16, 95-100.	6.7	98
67	Nasal and Exhaled Nitric Oxide Is Reduced in Adult Patients With Cystic Fibrosis and Does Not Correlate With Cystic Fibrosis Genotype. Chest, 2000, 117, 1085-1089.	0.8	105
68	Phagocyte oxidants and nitric oxide in cystic fibrosis: new therapeutic targets?. Current Opinion in Pulmonary Medicine, 2000, 6, 533-539.	2.6	13
69	Mouse models of chronic lung infection withPseudomonas Aeruginosa: Models for the study of cystic fibrosis. Pediatric Pulmonology, 2000, 30, 413-424.	2.0	51
70	Characterization of T cell clones derived from lymph nodes and lungs of Pseudomonas aeruginosa -susceptible and resistant mice following immunization with heat-killed bacteria. Clinical and Experimental Immunology, 2000, 121, 275-282.	2.6	19
71	Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clinical and Experimental Immunology, 2000, 120, 518-525.	2.6	107
72	Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by <i>Pseudomonas aeruginosa</i> . Clinical and Experimental Immunology, 2001, 122, 67-71.	2.6	34
73	Neutrophils: Molecules, Functions and Pathophysiological Aspects. Laboratory Investigation, 2000, 80, 617-653.	3.7	911
74	Airway surface liquid composition in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L1213-L1220.	2.9	30
75	Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-Î ³ . American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278,	2.9	73

#	Article	IF	CITATIONS
76	Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-α and interleukin-8. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L33-L41.	2.9	103
77	Myeloperoxidase and protein oxidation in cystic fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L537-L546.	2.9	178
78	Pseudomonas aeruginosa Exoenzyme S Induces Transcriptional Expression of Proinflammatory Cytokines and Chemokines. Infection and Immunity, 2000, 68, 4811-4814.	2.2	44
79	G551D Cystic Fibrosis Mice Exhibit Abnormal Regulation of Inflammation in Lungs and Macrophages. Journal of Immunology, 2000, 164, 3870-3877.	0.8	53
80	Adverse Alterations in Bone Metabolism Are Associated with Lung Infection in Adults with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1674-1678.	5.6	100
81	Innate Lung Defenses and Compromised Pseudomonas aeruginosa Clearance in the Malnourished Mouse Model of Respiratory Infections in Cystic Fibrosis. Infection and Immunity, 2000, 68, 2142-2147.	2.2	63
82	Mechanism of osteoporosis in patients with cystic fibrosis. Thorax, 2000, 55, 439-439.	5.6	3
83	Induction of Proinflammatory Cytokines from Human Respiratory Epithelial Cells after Stimulation by Nontypeable Haemophilus influenzae. Infection and Immunity, 2000, 68, 4430-4440.	2.2	53
84	INTERLEUKIN 10 (IL-10)-MEDIATED INHIBITION OF INFLAMMATORY CYTOKINE PRODUCTION BY HUMAN ALVEOLAR MACROPHAGES. Cytokine, 2000, 12, 1348-1355.	3.2	64
85	Inflammation in cystic fibrosis and its management. Paediatric Respiratory Reviews, 2000, 1, 101-106.	1.8	26
86	Intestinal inflammation in cystic fibrosis. Archives of Disease in Childhood, 2000, 82, 394-399.	1.9	117
87	TNF-A and IL-8 in Consecutive Sputum Samples from Cystic Fibrosis Patients During Antibiotic Treatment. Scandinavian Journal of Infectious Diseases, 2000, 32, 75-79.	1.5	53
88	Respiratory tract pathology and cytokine imbalance in clinically healthy children chronically and sequentially exposed to air pollutants. Medical Hypotheses, 2000, 55, 373-378.	1.5	7
89	A Clinical Inflammatory Syndrome Attributable to Aerosolized Lipid–DNA Administration in Cystic Fibrosis. Human Gene Therapy, 2001, 12, 751-761.	2.7	172
90	Regulation of Gap Junctional Communication by a Pro-Inflammatory Cytokine in Cystic Fibrosis Transmembrane Conductance Regulator-Expressing but Not Cystic Fibrosis Airway Cells. American Journal of Pathology, 2001, 158, 1775-1784.	3.8	65
91	Macrophages, neutrophils and tumour necrosis factor- α expression in bronchiectatic airways in vivo. Respiratory Medicine, 2001, 95, 792-798.	2.9	36
92	Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: A pilot study. Pediatric Pulmonology, 2001, 32, 293-302.	2.0	51
93	ROLE OF BRONCHOALVEOLAR LAVAGE IN INTERSTITIAL LUNG DISEASE. Clinics in Chest Medicine, 2001, 22, 331-341.	2.1	50

#	Article	IF	CITATIONS
94	Cystic Fibrosis and the Use of Pharmacogenomics to Determine Surrogate Endpoints for Drug Discovery. Molecular Diagnosis and Therapy, 2001, 1, 223-238.	3.3	10
95	CFTR and pseudomonas infections in cystic fibrosis. Frontiers in Bioscience - Landmark, 2001, 6, d890-897.	3.0	6
96	Mechanisms of insulin resistance in cystic fibrosis. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E1022-E1028.	3.5	99
97	Tumor necrosis factor-α/interleukin-10 balance in normal and cystic fibrosis children. Mediators of Inflammation, 2001, 10, 191-197.	3.0	36
98	Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. American Journal of Clinical Nutrition, 2001, 73, 602-606.	4.7	98
99	Interleukin-10. , 2001, 31, 269-273.		0
100	Proteomics as the Tool to Search for Lung Disease Markers in Bronchoalveolar Lavage. Disease Markers, 2001, 17, 271-284.	1.3	63
101	CFTR and pseudomonas infections in cystic fibrosis. Frontiers in Bioscience - Landmark, 2001, 6, d890.	3.0	22
102	Bacterial infections and inflammation in the lungs of cystic fibrosis patients. Pediatric Infectious Disease Journal, 2001, 20, 207-213.	2.0	29
103	Effects of extracellular pH on tumour necrosis factor-α production by resident alveolar macrophages. Clinical Science, 2001, 101, 267-274.	4.3	41
104	Effects of extracellular pH on tumour necrosis factor-α production by resident alveolar macrophages. Clinical Science, 2001, 101, 267.	4.3	18
105	Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients. European Respiratory Journal, 2001, 17, 36-38.	6.7	26
106	Frequency of Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations and 5T Allele in Patients With Allergic Bronchopulmonary Aspergillosis. Chest, 2001, 119, 762-767.	0.8	96
107	Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa. Clinical and Experimental Immunology, 2001, 124, 69-76.	2.6	104
108	Cystic fibrosis in three children with bronchopulmonary dysplasia. Pediatric Pulmonology, 2001, 31, 474-477.	2.0	2
109	Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: A pilot study. Pediatric Pulmonology, 2001, 32, 29-37.	2.0	82
110	Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis*. Pediatric Pulmonology, 2001, 32, 356-366.	2.0	361
111	Human airway mucin glycosylation: a combinatory of carbohydrate determinants which vary in cystic fibrosis. Glycoconjugate Journal, 2001, 18, 661-684.	2.7	153

#	Article	IF	CITATIONS
112	FAB-MS characterization of sialyl Lewis x determinants on polylactosamine chains of human airway mucins secreted by patients suffering from cystic fibrosis or chronic bronchitis. Glycoconjugate Journal, 2001, 18, 699-708.	2.7	12
113	Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation, 2001, 25, 145-155.	3.8	76
114	Inflammation and Cystic Fibrosis Pulmonary Disease. Pharmacotherapy, 2001, 21, 593-603.	2.6	12
115	Bronchial Inflammation and Colonization in Patients with Clinically Stable Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1628-1632.	5.6	223
116	Airway Inflammation in Children with Cystic Fibrosis and Healthy Children Assessed by Sputum Induction. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1425-1431.	5.6	160
117	Host Responses and Persistence of Vector Genome Following Intrabronchial Administration of an E1â^'E3â^' Adenovirus Gene Transfer Vector to Normal Individuals. Molecular Therapy, 2001, 3, 206-215.	8.2	31
118	Longitudinal Assessment ofPseudomonas aeruginosain Young Children with Cystic Fibrosis. Journal of Infectious Diseases, 2001, 183, 444-452.	4.0	520
119	Title is missing!. Mediators of Inflammation, 2001, 10, 191-197.	3.0	10
120	Growth Hormone Decreases Protein Catabolism in Children with Cystic Fibrosis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4424-4428.	3.6	47
121	A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies. Human Gene Therapy, 2002, 13, 1349-1359.	2.7	239
122	A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax, 2002, 57, 719-723.	5.6	63
123	ΔF508-CFTR Causes Constitutive NF-κB Activation through an ER-Overload Response in Cystic Fibrosis Lungs. Biological Chemistry, 2002, 383, 271-82.	2.5	63
124	Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities. Human Molecular Genetics, 2002, 11, 1059-1067.	2.9	50
125	Prolonged Inflammatory Response to Acute <i>Pseudomonas</i> Challenge in Interleukin-10 Knockout Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1176-1181.	5.6	73
126	Inflammatory Response in Airway Epithelial Cells Isolated from Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1248-1256.	5.6	115
127	Inflammatory Mediators in CF Patients. , 2002, 70, 409-432.		18
128	Tumor Necrosis Factor α Increases the Expression of Glycosyltransferases and Sulfotransferases Responsible for the Biosynthesis of Sialylated and/or Sulfated Lewis x Epitopes in the Human Bronchial Mucosa. Journal of Biological Chemistry, 2002, 277, 424-431.	3.4	117
129	Mechanisms and markers of airway inflammation in cystic fibrosis: Fig. 1.—. European Respiratory Journal, 2002, 19, 333-340.	6.7	87

#	Article	IF	CITATIONS
130	Global Genomic Analysis of AlgU (σE)-Dependent Promoters (Sigmulon) in Pseudomonas aeruginosa and Implications for Inflammatory Processes in Cystic Fibrosis. Journal of Bacteriology, 2002, 184, 1057-1064.	2.2	96
131	Functional IL-10 Deficiency in the Lung of Cystic Fibrosis (<i>cftr</i> â^'/â^') and IL-10 Knockout Mice Causes Increased Expression and Function of B7 Costimulatory Molecules on Alveolar Macrophages. Journal of Immunology, 2002, 168, 1903-1910.	0.8	78
132	Regulation of human airway epithelial cell IL-8 expression by MAP kinases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L690-L699.	2.9	127
133	Characterization of LPS-induced lung inflammation in <i>cftr</i> ^{â^'/â^'} mice and the effect of docosahexaenoic acid. Journal of Applied Physiology, 2002, 92, 2169-2176.	2.5	70
134	Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine, 2002, 8, 521-528.	2.6	28
135	Cytokine Profile of Chronic Sinusitis in Patients With Cystic Fibrosis. JAMA Otolaryngology, 2002, 128, 1295.	1.2	40
136	Sinobronchial Allergic Mycosis. Chest, 2002, 121, 1670-1676.	0.8	79
137	Macrolides in Cystic Fibrosis. Treatments in Respiratory Medicine, 2002, 1, 235-241.	1.2	16
139	Subclinical anaemia of chronic disease in adult patients with cystic fibrosis. Journal of Cystic Fibrosis, 2002, 1, 31-34.	0.7	18
140	Effects of pregnancy on health: certain aspects of importance for women with cystic fibrosis. Journal of Cystic Fibrosis, 2002, 1, 9-12.	0.7	14
141	Cell and cytokine profile in nasal secretions in cystic fibrosis. Journal of Cystic Fibrosis, 2002, 1, 110-115.	0.7	24
142	Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. Journal of Pediatrics, 2002, 141, 811-817.	1.8	132
143	Hyperacidification in cystic fibrosis: links with lung disease and new prospects for treatment. Trends in Molecular Medicine, 2002, 8, 512-519.	6.7	68
144	Persistent infections and immunity in cystic fibrosis. Frontiers in Bioscience - Landmark, 2002, 7, d442-457.	3.0	26
145	Therapy with Macrolides in Patients with Cystic Fibrosis. Pharmacotherapy, 2002, 22, 227-239.	2.6	33
146	Influence of gender and interleukin-10 deficiency on the inflammatory response during lung infection withPseudomonas aeruginosain mice. Immunology, 2002, 107, 297-305.	4.4	60
147	Symposium summaries S8.2-S13.3. Pediatric Pulmonology, 2002, 34, 127-152.	2.0	0
148	Synthesis of novel substituted isoquinolones. Tetrahedron, 2002, 58, 5761-5766.	1.9	31

#	Article	IF	CITATIONS
149	The Role of Inflammation in the Pathophysiology of CF Lung Disease. Clinical Reviews in Allergy and Immunology, 2002, 23, 005-028.	6.5	214
150	Use of Modulators of Airways Inflammation in Patients with CF. Clinical Reviews in Allergy and Immunology, 2002, 23, 029-040.	6.5	5
151	Monitoring Inflammation in CF: Cytokines. Clinical Reviews in Allergy and Immunology, 2002, 23, 041-058.	6.5	40
152	Modifier genes in cystic fibrosis lung disease. Translational Research, 2003, 141, 237-241.	2.3	70
153	Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis. Pediatric Pulmonology, 2003, 36, 43-48.	2.0	28
154	Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 918-951.	5.6	1,451
155	Metalloproteases from <i>Pseudomonas aeruginosa</i> Degrade Human RANTES, MCP-1, and ENA-78. Journal of Interferon and Cytokine Research, 2003, 23, 307-318.	1.2	58
156	State of the Art: Why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. Respiratory Research, 2003, 4, 8.	3.6	211
157	Severe Infections Caused by Pseudomonas Aeruginosa. Perspectives on Critical Care Infectious Diseases, 2003, , .	0.1	20
158	Balance of tumor necrosis factor alpha and interleukin-10 in a buccal infection in a streptozotocin-induced diabetic rat model. Cytokine, 2003, 24, 143-149.	3.2	9
161	Research applications of bronchoscopy. Paediatric Respiratory Reviews, 2003, 4, 230-236.	1.8	7
162	Inflammatory markers in cystic fibrosis patients with transmissiblePseudomonas aeruginosa. European Respiratory Journal, 2003, 22, 503-506.	6.7	46
163	Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. Journal of Medical Microbiology, 2003, 52, 731-740.	1.8	76
164	Microarray Analysis of Global Gene Expression in Mucoid Pseudomonas aeruginosa. Journal of Bacteriology, 2003, 185, 1071-1081.	2.2	150
165	Function and Bulk of Respiratory and Limb Muscles in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 989-994.	5.6	85
166	Uptake of18fluorodeoxyglucose in the cystic fibrosis lung: a measure of lung inflammation?. European Respiratory Journal, 2003, 21, 848-854.	6.7	28
167	Burkholderia cepacia–Induced IL-8 Gene Expression in an Alveolar Epithelial Cell Line: Signaling Through CD14 and Mitogen-Activated Protein Kinase. Pediatric Research, 2003, 54, 297-305.	2.3	36
168	Pseudomonas aeruginosa:Role in the Pathogenesis of the CF Lung Lesion. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 671-680.	2.1	17

#		IE	CITATIONS
#	IL-10 Controls Aspergillus fumigatus- and Pseudomonas aeruginosa-Specific T-Cell Response in Cystic	II	CHATIONS
169	Fibrosis. Pediatric Research, 2003, 53, 313-319.	2.3	28
170	Myeloid Related Protein-8/14 Stimulates Interleukin-8 Production in Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 523-530.	2.9	41
171	Inflammatory and Microbiologic Markers in Induced Sputum after Intravenous Antibiotics in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1471-1475.	5.6	160
172	End-Organ Dysfunction in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 384-389.	5.6	66
173	Noninvasive biomarkers of airway inflammation in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2003, 9, 516-521.	2.6	30
174	Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L997-L1003.	2.9	108
175	Cystic Fibrosis. Pathology Patterns Reviews, 2003, 120, S3-S13.	0.4	11
176	Signaling intermediates required for NF-κB activation and IL-8 expression in CF bronchial epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L307-L315.	2.9	51
177	Lung Inflammation as a Therapeutic Target in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 377-381.	2.9	100
178	Improvement of Alveolar Glutathione and Lung Function but Not Oxidative State in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 822-828.	5.6	104
179	Isoprenoid-Mediated Control of SMAD3 Expression in a Cultured Model of Cystic Fibrosis Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 234-240.	2.9	30
180	Submucosal Glands and Airway Defense. Proceedings of the American Thoracic Society, 2004, 1, 47-53.	3.5	192
181	Toll-Like Receptors in Normal and Cystic Fibrosis Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 777-783.	2.9	242
182	Microarray Analysis Reveals Induction of Lipoprotein Genes in Mucoid Pseudomonas aeruginosa : Implications for Inflammation in Cystic Fibrosis. Infection and Immunity, 2004, 72, 5012-5018.	2.2	61
183	Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7693-7698.	7.1	87
184	A short-term comparison of two methods of sputum expectoration in cystic fibrosis. European Respiratory Journal, 2004, 23, 435-439.	6.7	45
185	Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients. Thorax, 2004, 59, 1081-1088.	5.6	18
186	Interleukin 8 Secretion from Monocytes of Subjects Heterozygous for the ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutation Is Altered. Vaccine Journal, 2004, 11, 819-824.	2.6	77

#	Article	IF	CITATIONS
187	BALF Nitrite as an Indicator of Inflammation in Children with Cystic Fibrosis. Respiration, 2004, 71, 625-629.	2.6	14
188	Toward the pharmacogenomics of cystic fibrosis – an update. Pharmacogenomics, 2004, 5, 861-878.	1.3	5
189	Pseudomonas aeruginosa-Induced Neutrophilic Lung Inflammation Is Attenuated by Adenovirus-Mediated Transfer of the Heme Oxygenase 1 cDNA in Mice. Human Gene Therapy, 2004, 15, 273-285.	2.7	23
190	Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax, 2004, 59, 613-617.	5.6	56
191	Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients. Clinical and Experimental Immunology, 2004, 135, 528-534.	2.6	32
192	Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nature Immunology, 2004, 5, 388-392.	14.5	321
193	Effect of Pseudomonas-induced chronic lung inflammation on specific cytotoxic T-cell responses to adenoviral vectors in mice. Gene Therapy, 2004, 11, 1427-1433.	4.5	17
194	Faster activation of polymorphonuclear neutrophils in resistant mice during early innate response to Pseudomonas aeruginosa lung infection. Clinical and Experimental Immunology, 2004, 137, 478-485.	2.6	27
195	Quantitative cytokine gene expression in CF airway. Pediatric Pulmonology, 2004, 37, 393-399.	2.0	59
196	De la colonie microbienne à l'infection chez l'homme : le cas de Pseudomonas aeruginosa, importance thérapeutique. Antibiotiques, 2004, 6, 241-248.	0.1	0
197	Decreased interleukin-18 expression in BAL cells and peripheral blood mononuclear cells in adult cystic fibrosis patients. Journal of Cystic Fibrosis, 2004, 3, 129-131.	0.7	12
198	Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. Journal of Cystic Fibrosis, 2004, 3, 67-91.	0.7	265
199	Cytokines and inflammatory mediators in cystic fibrosis. Journal of Cystic Fibrosis, 2004, 3, 223-231.	0.7	106
200	Solidâ€Phase One Step Synthesis of 4H,4′â€Exomethyleneâ€bis[quinazolinâ€2â€enols]. Synthetic Communica 2004, 34, 1819-1823.	ations, 2.1	9
201	Pharmacokinetics of Ibuprofen in Children with Cystic Fibrosis. Clinical Pharmacokinetics, 2004, 43, 145-156.	3.5	7
202	Involvement of p38 and p42/44 MAP kinases and protein kinase C in the interferon-Î ³ and interleukin-1α-induced phosphorylation of 85-kDa cytosolic phospholipase A2 in primary human bronchial epithelial cells. Cytokine, 2004, 25, 11-20.	3.2	23
203	Interleukin-8 in whole blood and clinical status in cystic fibrosis. Cytokine, 2004, 29, 18-23.	3.2	19
204	Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis. Journal of Pediatrics, 2004, 145, 689-692.	1.8	33

#	Article	IF	CITATIONS
205	Airway Glycoconjugates Secreted in Cystic Fibrosis and Severe Chronic Airway Inflammation Relationship with Pseudomonas aeruginosa. , 2005, , 145-167.		0
207	Downregulation of ENaC activity and expression by TNF-α in alveolar epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L301-L311.	2.9	128
208	Is there a case for n-3 fatty acid supplementation in cystic fibrosis?. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 153-159.	2.5	23
209	Down-regulation of IL-8 expression in human airway epithelial cells through helper-dependent adenoviral-mediated RNA interference. Cell Research, 2005, 15, 111-119.	12.0	27
210	Amphiphilic pyridinium salts block TNFα/NFκB signaling and constitutive hypersecretion of interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells. Biochemical Pharmacology, 2005, 70, 381-393.	4.4	22
211	Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radical Biology and Medicine, 2005, 39, 463-472.	2.9	53
212	Antiinflammatory Therapies for Cystic Fibrosis: Past, Present, and Future. Pharmacotherapy, 2005, 25, 555-573.	2.6	36
213	Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronicPseudomonas aeruginosa lung infection. Pediatric Pulmonology, 2005, 39, 141-149.	2.0	37
214	Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatric Pulmonology, 2005, 40, 15-21.	2.0	88
215	Lower Airway Inflammation in Infants with Cystic Fibrosis Detected by Newborn Screening. Pediatric Pulmonology, 2005, 40, 500-510.	2.0	205
216	Biomarkers of Neutrophilic Inflammation in Exhaled Air of Cystic Fibrosis Children with Bacterial Airway Infections. Pediatric Pulmonology, 2005, 40, 494-499.	2.0	54
217	Pathogenesis of Early Lung Disease in Cystic Fibrosis: A Window of Opportunity To Eradicate Bacteria. Annals of Internal Medicine, 2005, 143, 816.	3.9	48
218	Infection versus Inflammation. , 2005, 34, 122-130.		0
219	Differential effects of α- and β-defensin on cytokine production by cultured human bronchial epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L508-L513.	2.9	83
220	NF-κB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated withPseudomonas aeruginosa. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L471-L479.	2.9	93
221	Interleukin-1, Neutrophil Elastase, and Lipopolysaccharide: Key Pro- Inflammatory Stimuli Regulating Inflammation in Cystic Fibrosis. Current Respiratory Medicine Reviews, 2005, 1, 43-67.	0.2	6
222	Cystic fibrosis lung disease following infection with Pseudomonas aeruginosa in Cftr knockout mice using novel non-invasive direct pulmonary infection technique. Laboratory Animals, 2005, 39, 336-352.	1.0	44
223	Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2005, 49, 5013-5017.	3.2	46

#	Article	IF	CITATIONS
224	Surfactant replacement does not reduce duration of ventilatory support in paediatric acute lung injury. Thorax, 2005, 60, 325-325.	5.6	0
226	Endothelial Activation and Increased Heparan Sulfate Expression in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 892-898.	5.6	44
227	Pyocyanin Production by <i>Pseudomonas aeruginosa</i> Induces Neutrophil Apoptosis and Impairs Neutrophil-Mediated Host Defenses In Vivo. Journal of Immunology, 2005, 174, 3643-3649.	0.8	219
228	Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax, 2005, 60, 659-664.	5.6	83
229	Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax, 2005, 60, 320-325.	5.6	42
230	Similarity of Gene Expression Patterns in Human Alveolar Macrophages in Response to Pseudomonas aeruginosa and Burkholderia cepacia. Infection and Immunity, 2005, 73, 5262-5268.	2.2	6
231	Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Annals of Allergy, Asthma and Immunology, 2005, 95, 372-380.	1.0	37
232	Effect of cystic fibrosis exacerbations on neutrophil function. International Immunopharmacology, 2005, 5, 601-608.	3.8	27
233	Circulating markers to assess nutritional therapy in cystic fibrosis. Clinica Chimica Acta, 2005, 353, 13-29.	1.1	12
234	Cystic fibrosis and lipoxins. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 263-270.	2.2	34
235	Identifying Novel Endpoints for Cystic Fibrosis Clinical Trials. Advances in Pediatrics, 2005, 52, 115-127.	1.4	1
236	The role of airway epithelium and blood neutrophils in the inflammatory response in cystic fibrosis. Journal of Cystic Fibrosis, 2005, 4, 15-23.	0.7	35
237	Role of IL-10 deficiency in excessive nuclear factor-l [°] B activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. Journal of Allergy and Clinical Immunology, 2005, 115, 405-411.	2.9	55
238	Pre-clinical and clinical endpoint assays for cystic fibrosis gene therapy. Journal of Cystic Fibrosis, 2005, 4, 89-100.	0.7	22
239	Infection and inflammation in cystic fibrosis: A short review. Journal of Cystic Fibrosis, 2005, 4, 3-5.	0.7	113
240	Motorcycle Exhaust Particles Induce IL-8 Production Through NF-κB Activation in Human Airway Epithelial Cells. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2005, 68, 1537-1555.	2.3	15
241	Anti-Inflammatory Medications for Cystic Fibrosis Lung Disease. Treatments in Respiratory Medicine, 2005, 4, 255-273.	1.4	31
242	Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice. Respiratory Research, 2006, 7, 134.	3.6	88

#	Article	IF	CITATIONS
243	Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. Respiratory Research, 2006, 7, 51.	3.6	22
244	Pulmonary TH2 response in Pseudomonas aeruginosa–infected patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2006, 117, 204-211.	2.9	172
245	Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-κB activation, cytokine secretion, and persistent lung inflammation. Journal of Allergy and Clinical Immunology, 2006, 117, 1163-1169.	2.9	32
246	Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia. Journal of Cystic Fibrosis, 2006, 5, 145-151.	0.7	36
247	Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochemical and Biophysical Research Communications, 2006, 350, 977-982.	2.1	103
248	Pre-transplant Soluble CD30 Is Associated With Bronchiolitis Obliterans Syndrome After Lung Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 416-419.	0.6	22
249	Cystic fibrosis pulmonary exacerbations. Journal of Pediatrics, 2006, 148, 259-264.	1.8	139
250	Cachexia: lessons from melanocortin antagonism. Trends in Endocrinology and Metabolism, 2006, 17, 199-204.	7.1	46
251	Cytokines in the Nasal Washes of Children with Respiratory Syncytial Virus Bronchiolitis. International Journal of Immunopathology and Pharmacology, 2006, 19, 205873920601900.	2.1	18
252	Symposium Session Summaries. Pediatric Pulmonology, 2006, 41, 93-208.	2.0	0
253	Enhanced IgE allergic response to Aspergillus fumigatus in CFTRâ^'/â^' mice. Laboratory Investigation, 2006, 86, 130-140.	3.7	29
254	Endosomal hyperacidification in cystic fibrosis is due to defective nitric oxide–cylic GMP signalling cascade. EMBO Reports, 2006, 7, 553-559.	4.5	29
255	Relationship between insulin-like growth factorÂl, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis. Osteoporosis International, 2006, 17, 783-790.	3.1	30
256	Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 65-77.	3.0	24
257	Respiratory syncytial virus infection in a murine model of cystic fibrosis. Journal of Medical Virology, 2006, 78, 651-658.	5.0	41
258	Adenosine Regulation of Cystic Fibrosis Transmembrane Conductance Regulator through Prostenoids in Airway Epithelia. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 600-608.	2.9	44
259	Characterizing Mucous Cell Remodeling in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1018-1024.	5.6	42
260	Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L75-L85.	2.9	136

#	Article	lF	CITATIONS
261	Inhaled heparin in cystic fibrosis. European Respiratory Journal, 2006, 27, 354-358.	6.7	38
262	Anti-inflammatory cytokines in cystic fibrosis lung disease. European Respiratory Journal, 2006, 28, 581-587.	6.7	43
263	De Novo Biosynthetic Profiling of High Abundance Proteins in Cystic Fibrosis Lung Epithelial Cells. Molecular and Cellular Proteomics, 2006, 5, 1628-1637.	3.8	44
264	The Type III Pseudomonal Exotoxin U Activates the c-Jun NH2-Terminal Kinase Pathway and Increases Human Epithelial Interleukin-8 Production. Infection and Immunity, 2006, 74, 4104-4113.	2.2	37
265	Nonclassical Pathway of Pseudomonas aeruginosa DNA-Induced Interleukin-8 Secretion in Cystic Fibrosis Airway Epithelial Cells. Infection and Immunity, 2006, 74, 2975-2984.	2.2	29
266	Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax, 2006, 61, 592-596.	5.6	35
267	Cutting Edge: Enhanced Pulmonary Clearance of <i>Pseudomonas aeruginosa</i> by Muc1 Knockout Mice. Journal of Immunology, 2006, 176, 3890-3894.	0.8	126
268	Growth Hormone Normalizes Pubertal Onset in Children with Cystic Fibrosis. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 237-44.	0.9	15
269	Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis. Thorax, 2007, 62, 360-367.	5.6	377
270	Resistance to Pseudomonas aeruginosa Chronic Lung Infection Requires Cystic Fibrosis Transmembrane Conductance Regulator-Modulated Interleukin-1 (IL-1) Release and Signaling through the IL-1 Receptor. Infection and Immunity, 2007, 75, 1598-1608.	2.2	66
271	Parthenolide Inhibits ll̂ºB Kinase, NF-l̂ºB Activation, and Inflammatory Response in Cystic Fibrosis Cells and Mice. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 728-736.	2.9	125
272	PAR-2 activation and LPS synergistically enhance inflammatory signaling in airway epithelial cells by raising PAR expression level and interleukin-8 release. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L1208-L1218.	2.9	41
273	IL-23 mediates inflammatory responses to mucoidPseudomonas aeruginosalung infection in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L519-L528.	2.9	182
274	Inflammation in Cystic Fibrosis-When and Why? Friend or Foe?. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 286-294.	2.1	11
275	Ghrelin Treatment Causes Increased Food Intake and Retention of Lean Body Mass in a Rat Model of Cancer Cachexia. Endocrinology, 2007, 148, 3004-3012.	2.8	162
276	MPB-07 Reduces the Inflammatory Response toPseudomonas aeruginosain Cystic Fibrosis Bronchial Cells. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 615-624.	2.9	39
277	Nitrosative stress inhibits production of the virulence factor alginate in mucoidPseudomonas aeruginosa. Free Radical Research, 2007, 41, 208-215.	3.3	13
278	Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. European Respiratory Journal, 2007, 29, 965-968.	6.7	50

#	Article	IF	CITATIONS
279	Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-κB activation in a cystic fibrosis epithelial cell line. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L343-L352.	2.9	58
280	Azithromycin Selectively Reduces Tumor Necrosis Factor Alpha Levels in Cystic Fibrosis Airway Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2007, 51, 975-981.	3.2	95
281	Airway remodelling in children with cystic fibrosis. Thorax, 2007, 62, 1074-1080.	5.6	119
282	Validation of an automated sensitive immunoassay for quantitation of cytokines in the sputum of cystic fibrosis patients. Clinical Chemistry and Laboratory Medicine, 2007, 45, 108-11.	2.3	8
283	Novel Neutrophil-Derived Proteins in Bronchoalveolar Lavage Fluid Indicate an Exaggerated Inflammatory Response in Pediatric Cystic Fibrosis Patients. Clinical Chemistry, 2007, 53, 1782-1791.	3.2	45
284	TNF-α levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy. Growth Hormone and IGF Research, 2007, 17, 149-153.	1.1	28
285	Inflammation and Anti-Inflammatory Therapies for Cystic Fibrosis. Clinics in Chest Medicine, 2007, 28, 331-346.	2.1	85
286	Serum myeloperoxidase in cystic fibrosis patients receiving systemic antibiotics. Scandinavian Journal of Infectious Diseases, 2007, 39, 163-166.	1.5	6
287	Use of high-dose ibuprofen in a pediatric cystic fibrosis center. Journal of Cystic Fibrosis, 2007, 6, 153-158.	0.7	30
288	Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease. Proceedings of the American Thoracic Society, 2007, 4, 406-417.	3.5	148
289	Exploring host-pathogen interactions at the epithelial surface: application of transcriptomics in lung biology. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L367-L377.	2.9	8
290	Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 256-262.	2.0	61
291	Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nature Medicine, 2007, 13, 1423-1430.	30.7	291
292	Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clinical and Experimental Immunology, 2007, 147, 540-546.	2.6	85
293	Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling. Clinical Reviews in Allergy and Immunology, 2008, 34, 146-162.	6.5	117
294	Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease. Clinical Reviews in Allergy and Immunology, 2008, 35, 135-153.	6.5	37
295	Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 209-219.	2.0	38
296	Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes and Immunity, 2008, 9, 501-508.	4.1	59

#	Article	IF	Citations
297	Exogenous nitric oxide regulates cyclooxygenase-2 expression and prostaglandin D2 generation through p38 MAPK in mouse bone marrow-derived mast cells. Free Radical Biology and Medicine, 2008, 45, 780-788.	2.9	10
299	IL-6 and IL-8 increase the expression of glycosyltransferases and sulfotransferases involved in the biosynthesis of sialylated and/or sulfated Lewisx epitopes in the human bronchial mucosa. Biochemical Journal, 2008, 410, 213-223.	3.7	72
300	Feasibility of nasal epithelial brushing for the study of airway epithelial functions in CF infants. Journal of Cystic Fibrosis, 2008, 7, 44-53.	0.7	41
301	Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. Journal of Cystic Fibrosis, 2008, 7, 68-78.	0.7	52
302	Association of interleukin-10 gene haplotypes with Pseudomonas aeruginosa airway colonization in cystic fibrosis. Journal of Cystic Fibrosis, 2008, 7, 329-332.	0.7	11
303	Anti-inflammatory effect of miglustat in bronchial epithelial cells. Journal of Cystic Fibrosis, 2008, 7, 555-565.	0.7	45
304	Neutrophil Elastase (NE) and NE Inhibitors: Canonical and Noncanonical Functions in Lung Chronic Inflammatory Diseases (Cystic Fibrosis and Chronic Obstructive Pulmonary Disease). Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 125-144.	1.4	56
305	The Role of Central Melanocortins in Cachexia. , 2007, , 59-68.		0
306	Protease-activated receptor (PAR)-induced interleukin-8 production in airway epithelial cells requires activation of MAP kinases p44/42 and JNK. Biochemical and Biophysical Research Communications, 2008, 366, 1030-1035.	2.1	15
307	Circulating and airway neutrophils in cystic fibrosis display different TLR expression and responsiveness to interleukin-10. Cytokine, 2008, 41, 54-60.	3.2	47
308	Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy, 2008, 61, 554-560.	3.0	160
311	Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. European Respiratory Journal, 2008, 31, 396-406.	6.7	171
312	Evaluation of in vitro virulence characteristics of the genus Pandoraea in lung epithelial cells. Journal of Medical Microbiology, 2008, 57, 15-20.	1.8	44
313	Inhibition of airway proteases in cystic fibrosis lung disease. European Respiratory Journal, 2008, 32, 783-795.	6.7	94
314	Assessment and monitoring of cystic fibrosis lung disease in infants and young children. Expert Review of Respiratory Medicine, 2008, 2, 381-390.	2.5	0
315	TLR Expression on Neutrophils at the Pulmonary Site of Infection: TLR1/TLR2-Mediated Up-Regulation of TLR5 Expression in Cystic Fibrosis Lung Disease. Journal of Immunology, 2008, 181, 2753-2763.	0.8	86
316	Transcription Factor Oligodeoxynucleotides to NF-κB Inhibit Transcription of IL-8 in Bronchial Cells. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 86-96.	2.9	49
317	Expression of Cyclooxygenase and Lipoxygenase Enzymes in Sinonasal Mucosa of Patients With Cystic Fibrosis. JAMA Otolaryngology, 2008, 134, 825.	1.2	20

#	Article	IF	CITATIONS
318	Evaluation of Tumour Necrosis Factor-Alpha and Interleukin-1beta in an Experimental Pyelonephritis Model Induced with Planktonic and Biofilms Cells of <i>Pseudomonas aeruginosa</i> . Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e35-e42.	1.9	13
319	TNFÂ-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. Thorax, 2009, 64, 1044-1052.	5.6	29
320	Azithromycin Reduces Exaggerated Cytokine Production by M1 Alveolar Macrophages in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 590-602.	2.9	109
321	Defective Acid Sphingomyelinase Pathway withPseudomonas aeruginosaInfection in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 367-375.	2.9	52
322	Loss of CFTR results in reduction of histone deacetylase 2 in airway epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L35-L43.	2.9	27
323	Oxidative Stress Causes <i>IL8</i> Promoter Hyperacetylation in Cystic Fibrosis Airway Cell Models. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 58-65.	2.9	65
324	Tristetraprolin regulates IL-8 mRNA stability in cystic fibrosis lung epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L1012-L1018.	2.9	35
325	Stabilization of Lung Function and Clinical Symptoms in a Patient with Cystic Fibrosis (CF) After Institution of Infliximab: A Monoclonal Antibody that Binds Tumor Necrosis Factor alpha. Lung, 2009, 187, 149-152.	3.3	10
326	Innate immune receptors on neutrophils and their role in chronic lung disease. European Journal of Clinical Investigation, 2009, 39, 535-547.	3.4	35
327	The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftrâ^'/â^'-dependent allergy mouse model. Gene Therapy, 2009, 16, 172-183.	4.5	17
328	Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. BioFactors, 2009, 35, 165-168.	5.4	53
329	Influence of the cystic fibrosis transmembrane conductance regulator on expression of lipid metabolism-related genes in dendritic cells. Respiratory Research, 2009, 10, 26.	3.6	27
330	The Role of Inhaled Corticosteroids in the Management of Cystic Fibrosis. Paediatric Drugs, 2009, 11, 101-113.	3.1	35
331	Virtual screening against nuclear factor κB (NF-κB) of a focus library: Identification of bioactive furocoumarin derivatives inhibiting NF-κB dependent biological functions involved in cystic fibrosis. Bioorganic and Medicinal Chemistry, 2010, 18, 8341-8349.	3.0	37
332	Decoy oligodeoxyribonucleotides and peptide nucleic acids–DNA chimeras targeting nuclear factor kappa-B: Inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa. Biochemical Pharmacology, 2010, 80, 1887-1894.	4.4	41
333	Diastereoselective approach to novel octahydroisoquinolones and an extension to its one-pot synthesis. Tetrahedron Letters, 2010, 51, 4272-4274.	1.4	25
334	Isolation and characterization of microparticles in sputum from cystic fibrosis patients. Respiratory Research, 2010, 11, 94.	3.6	50
335	Effects of a shortâ€ŧerm rehabilitation program on airway inflammation in children with cystic fibrosis. Pediatric Pulmonology, 2010, 45, 541-551.	2.0	14

#	Article	IF	Citations
336	Symposium Summaries. Pediatric Pulmonology, 2010, 45, 107-219.	2.0	5
337	Macrophage responses to CF pathogens: JNK MAP kinase signaling by Burkholderia cepacia complex lipopolysaccharide. FEMS Immunology and Medical Microbiology, 2010, 60, 36-43.	2.7	10
338	IL-10 delivery by AAV5 vector attenuates inflammation in mice with pseudomonas pneumonia. Gene Therapy, 2010, 17, 567-576.	4.5	31
339	Potential of anti-inflammatory treatment for cystic fibrosis lung disease. Journal of Inflammation Research, 2010, 3, 61.	3.5	11
340	Antiproteases as Therapeutics to Target Inflammation in Cystic Fibrosis. Open Respiratory Medicine Journal, 2010, 4, 20-31.	0.4	13
341	High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals, 2010, 3, 2213-2224.	3.8	25
342	Estrogen Receptor-α as a Drug Target Candidate for Preventing Lung Inflammation. Endocrinology, 2010, 151, 174-184.	2.8	61
343	Loss of Cystic Fibrosis Transmembrane Conductance Regulator Function Enhances Activation of p38 and ERK MAPKs, Increasing Interleukin-6 Synthesis in Airway Epithelial Cells Exposed to Pseudomonas aeruginosa. Journal of Biological Chemistry, 2010, 285, 22299-22307.	3.4	78
344	Role of Excessive Inflammatory Response to <i>Stenotrophomonas maltophilia</i> Lung Infection in DBA/2 Mice and Implications for Cystic Fibrosis. Infection and Immunity, 2010, 78, 2466-2476.	2.2	48
345	Targeting Inflammation in Cystic Fibrosis. Respiration, 2010, 79, 189-190.	2.6	9
346	TLR-4–Mediated Innate Immunity Is Reduced in Cystic Fibrosis Airway Cells. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 424-431.	2.9	81
347	Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Lung Infection with Pseudomonas. Antimicrobial Agents and Chemotherapy, 2010, 54, 2437-2447.	3.2	81
348	Induction by TNF-αof IL-6 and IL-8 in Cystic Fibrosis Bronchial IB3-1 Epithelial Cells Encapsulated in Alginate Microbeads. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-11.	3.0	13
349	In Vitro Inhibition of Neutrophil Elastase Activity by Inhaled Anti-Pseudomonas Antibiotics Used in Cystic Fibrosis Patients. Mediators of Inflammation, 2010, 2010, 1-5.	3.0	5
350	Targeting Transcription Factor Activity as a Strategy to Inhibit Pro- Inflammatory Genes Involved in Cystic Fibrosis: Decoy Oligonucleotides and Low-Molecular Weight Compounds. Current Medicinal Chemistry, 2010, 17, 4392-4404.	2.4	32
351	17β-Estradiol Inhibits IL-8 in Cystic Fibrosis by Up-Regulating Secretory Leucoprotease Inhibitor. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 62-72.	5.6	85
352	Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. Journal of Cystic Fibrosis, 2010, 9, 51-58.	0.7	136
353	Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice. Respiratory Research, 2010, 11, 166.	3.6	83

#	Article	IF	CITATIONS
354	Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 649-658.	3.8	28
355	CFTR Inhibition Provokes an Inflammatory Response Associated with an Imbalance of the Annexin A1 Pathway. American Journal of Pathology, 2010, 177, 176-186.	3.8	31
356	Reduced surface toll-like receptor-4 expression and absent interferon-γ–inducible protein-10 induction in cystic fibrosis airway cells. Experimental Lung Research, 2011, 37, 319-326.	1.2	18
357	Elevated miR-155 Promotes Inflammation in Cystic Fibrosis by Driving Hyperexpression of Interleukin-8. Journal of Biological Chemistry, 2011, 286, 11604-11615.	3.4	196
358	Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis. Clinical Microbiology Reviews, 2011, 24, 29-70.	13.6	341
359	Targeting Airway Inflammation in Cystic Fibrosis in Children. Paediatric Drugs, 2011, 13, 141-147.	3.1	20
360	Complex <i>Pseudomonas</i> Population Structure in Cystic Fibrosis Airway Infections. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1581-1583.	5.6	14
361	Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin. Journal of Cystic Fibrosis, 2011, 10, 166-174.	0.7	18
362	Effect of Ambroxol on Pneumonia Caused by <i>Pseudomonas aeruginosa</i> with Biofilm Formation in an Endotracheal Intubation Rat Model. Chemotherapy, 2011, 57, 173-180.	1.6	19
363	Development of a novel furocoumarin derivative inhibiting NF-κB dependent biological functions: Design, synthesis and biological effects. European Journal of Medicinal Chemistry, 2011, 46, 4870-4877.	5.5	38
364	Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells. Journal of Inflammation, 2011, 8, 26.	3.4	34
365	Bergamot (Citrus bergamia Risso) fruit extracts and identified components alter expression of interleukin 8 gene in cystic fibrosis bronchial epithelial cell lines. BMC Biochemistry, 2011, 12, 15.	4.4	34
366	Sustained inhibition of ILâ€6 and ILâ€8 expression by decoy ODN to NFâ€ՔB delivered through respirable large porous particles in LPSâ€stimulated cystic fibrosis bronchial cells. Journal of Gene Medicine, 2011, 13, 200-208.	2.8	29
368	Autophagy stimulation by rapamycin suppresses lung inflammation and infection by <i>Burkholderia cenocepacia</i> in a model of cystic fibrosis. Autophagy, 2011, 7, 1359-1370.	9.1	180
369	Phospholipase C-β3 Is a Key Modulator of IL-8 Expression in Cystic Fibrosis Bronchial Epithelial Cells. Journal of Immunology, 2011, 186, 4946-4958.	0.8	34
370	Pharmacokinetics and Diffusion into Sputum of Oseltamivir and Oseltamivir Carboxylate in Adults with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 4183-4187.	3.2	6
371	Down-regulation of Cytokine-induced Interleukin-8 Requires Inhibition of p38 Mitogen-activated Protein Kinase (MAPK) via MAPK Phosphatase 1-dependent and -independent Mechanisms. Journal of Biological Chemistry, 2011, 286, 15998-16007.	3.4	31
372	Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset. Expert Review of Molecular Diagnostics, 2011, 11, 197-206.	3.1	16

		IATION REPORT	
#	Article	IF	CITATIONS
373	Regulation of normal and cystic fibrosis airway epithelial repair processes by TNF-α after injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 301, L945-L955.	2.9	36
374	MAPK signaling pathways regulate IL-8 mRNA stability and IL-8 protein expression in cystic fibrosis lun epithelial cell lines. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L81-L87.	g 2.9	47
375	Trimethylangelicin reduces IL-8 transcription and potentiates CFTR function. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L380-L390.	2.9	34
376	Ambient Particulate Matter Induces Interleukin-8 Expression through an Alternative NF-κB (Nuclear) T 119, 1379-1383.	ETQq1 1 0.7843 6.0	14 rgBT /Overlo 49
377	Macrophage-Mediated Inflammation and Disease: A Focus on the Lung. Mediators of Inflammation, 20 2012, 1-6.)12, 3.0	59
378	Interaction with CREB binding protein modulates the activities of Nrf2 and NF-κB in cystic fibrosis airway epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L1221-L1231.	2.9	51
379	Interleukin-23-Mediated Inflammation in Pseudomonas aeruginosa Pulmonary Infection. Infection and Immunity, 2012, 80, 398-409.	2.2	56
380	Inflammatory Cytokines of Cystic Fibrosis Airway Cells Are Reduced with Exposure to Interleukin-10. Pediatric, Allergy, Immunology, and Pulmonology, 2012, 25, 213-219.	0.8	1
381	Effects of decoy molecules targeting NF-kappaB transcription factors in Cystic fibrosis IB3–1 cells. Artificial DNA, PNA & XNA, 2012, 3, 97-104.	1.4	25
382	Activation of the Pyrin Inflammasome by Intracellular <i>Burkholderia cenocepacia</i> . Journal of Immunology, 2012, 188, 3469-3477.	0.8	115
383	Absence of the cystic fibrosis transmembrane regulator (<i>Cftr</i>) from myeloid-derived cells slows resolution of inflammation and infection. Journal of Leukocyte Biology, 2012, 92, 1111-1122.	3.3	127
384	HIV-related bronchiectasis in children: an emerging spectre in high tuberculosis burden areas. International Journal of Tuberculosis and Lung Disease, 2012, 16, 114-119.	1.2	37
385	Immune Effects of Interferon Gamma in Persistent Staphylococcal Sepsis. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 110-112.	5.6	58
386	Interleukin-17 and Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 109-110.	5.6	3
387	Antimicrobial and anti-inflammatory effects of clarithromycin on Mycobacterium avium complex replication in cultured human bronchial epithelial cells. Journal of Infection and Chemotherapy, 2012, 18, 683-688.	1.7	3
388	Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen. Clinical Microbiology Reviews, 2012, 25, 2-41.	13.6	1,062
389	Corilagin is a potent inhibitor of NF-kappaB activity and downregulates TNF-alpha induced expression of IL-8 gene in cystic fibrosis IB3-1 cells. International Immunopharmacology, 2012, 13, 308-315.	3.8	59
390	Oxidative stress and antioxidant therapy in cystic fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 690-713.	3.8	186

#	ARTICLE	IF	CITATIONS
391	Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from Cystic fibrosis patients. Biochemical and Biophysical Research Communications, 2012, 424, 221-227.	2.1	47
392	Macrophage Migration Inhibitory Factor Enzymatic Activity, Lung Inflammation, and Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 162-169.	5.6	46
393	A heat-stable cytotoxic factor produced by Achromobacter xylosoxidans isolated from Brazilian patients with CF is associated with in vitro increased proinflammatory cytokines. Journal of Cystic Fibrosis, 2012, 11, 305-311.	0.7	22
394	Innate immunity in cystic fibrosis lung disease. Journal of Cystic Fibrosis, 2012, 11, 363-382.	0.7	191
395	Pulmonary Disease in Cystic Fibrosis. , 2012, , 770-780.		6
396	Inflammasome-Mediated IL- 1^2 Production in Humans with Cystic Fibrosis. PLoS ONE, 2012, 7, e37689.	2.5	54
397	Sputum Biomarkers and the Prediction of Clinical Outcomes in Patients with Cystic Fibrosis. PLoS ONE, 2012, 7, e42748.	2.5	57
398	Immune Dysfunction in Cystic Fibrosis. , 0, , .		2
399	CpG-free plasmid expression cassettes for cystic fibrosis gene therapy. Biomaterials, 2012, 33, 6833-6842.	11.4	12
400	CFTR negatively regulates cyclooxygenaseâ€2â€PGE ₂ positive feedback loop in inflammation. Journal of Cellular Physiology, 2012, 227, 2759-2766.	4.1	40
401	MicroRNA Cancer Regulation. Advances in Experimental Medicine and Biology, 2013, , .	1.6	17
402	Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis, 2013, 12, 623-629.	0.7	20
403	Alpinetin attenuates inflammatory responses by interfering toll-like receptor 4/nuclear factor kappa B signaling pathway in lipopolysaccharide-induced mastitis in mice. International Immunopharmacology, 2013, 17, 26-32.	3.8	39
404	CFTR activity and mitochondrial function. Redox Biology, 2013, 1, 190-202.	9.0	64
405	Differential Regulation of Inflammation by Inflammatory Mediators in Cystic Fibrosis Lung Epithelial Cells. Journal of Interferon and Cytokine Research, 2013, 33, 121-129.	1.2	37
406	The Impact of Cystic Fibrosis on the Immunologic Profile of Pediatric Patients. Jornal De Pediatria, 2013, 89, 40-47.	2.0	17
407	The impact of cystic fibrosis on the immunologic profile of pediatric patients. Jornal De Pediatria (Versão Em Português), 2013, 89, 40-47.	0.2	0
408	Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertility and Sterility, 2013, 100, 178-193.	1.0	150

#	Article	IF	CITATIONS
409	Regulation of miR-155 biogenesis in cystic fibrosis lung epithelial cells: Antagonistic role of two mRNA-destabilizing proteins, KSRP and TTP. Biochemical and Biophysical Research Communications, 2013, 433, 484-488.	2.1	36
410	How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis. Lancet Respiratory Medicine,the, 2013, 1, 137-147.	10.7	39
411	MicroRNAs in the Lung. Advances in Experimental Medicine and Biology, 2013, 774, 121-134.	1.6	26
412	Response of CFTR-Deficient Mice to Long-Term chronic Pseudomonas aeruginosa Infection and PTX3 Therapy. Journal of Infectious Diseases, 2013, 208, 130-138.	4.0	39
413	Uterine Fibroids: Pathogenesis and Interactions with Endometrium and Endomyometrial Junction. Obstetrics and Gynecology International, 2013, 2013, 1-11.	1.3	136
414	Modulation of the Expression of the Proinflammatory IL-8 Gene in Cystic Fibrosis Cells by Extracts Deriving from Olive Mill Waste Water. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-11.	1.2	15
415	Expression and Regulation of Interferon-Related Development Regulator–1 in Cystic Fibrosis Neutrophils. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 71-77.	2.9	12
416	The Level of p38α Mitogen-Activated Protein Kinase Activation in Airway Epithelial Cells Determines the Onset of Innate Immune Responses to Planktonic and Biofilm Pseudomonas aeruginosa. Journal of Infectious Diseases, 2013, 207, 1544-1555.	4.0	25
417	Antibiotic and Anti-Inflammatory Therapies for Cystic Fibrosis. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a009779-a009779.	6.2	54
418	Efficient delivery of RNA interference oligonucleotides to polarized airway epithelia in vitro. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 305, L23-L32.	2.9	41
419	Host mucin glycosylation plays a role in bacterial adhesion in lungs of individuals with cystic fibrosis. Expert Review of Respiratory Medicine, 2013, 7, 553-576.	2.5	44
420	Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in the Lower Airways in COPD. Chest, 2013, 144, 498-506.	0.8	163
421	Normal CFTR Inhibits Epidermal Growth Factor Receptor-Dependent Pro-Inflammatory Chemokine Production in Human Airway Epithelial Cells. PLoS ONE, 2013, 8, e72981.	2.5	24
422	Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. Journal of Inflammation Research, 2013, 6, 1.	3.5	43
423	Cystic Fibrosis Pulmonary Exacerbation $\hat{a} \in \hat{~}$ Natural History, Causative Factors and Management. , 0, , .		0
424	Evaluation of Genome-Wide Expression Profiles of Blood and Sputum Neutrophils in Cystic Fibrosis Patients Before and After Antibiotic Therapy. PLoS ONE, 2014, 9, e104080.	2.5	14
425	Impact of MIF Gene Promoter Polymorphism on F508del Cystic Fibrosis Patients. PLoS ONE, 2014, 9, e114274.	2.5	7
426	β-Defensin 2 Ameliorates Lung Injury Caused by Pseudomonas Infection and Regulates Proinflammatory and Anti-Inflammatory Cytokines in Rat. International Journal of Molecular Sciences, 2014, 15, 13372-13387	4.1	12

#	Article	IF	CITATIONS
427	CFTR and lung homeostasis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L917-L923.	2.9	73
428	Modulation of Treg function improves adenovirus vector-mediated gene expression in the airway. Gene Therapy, 2014, 21, 219-224.	4.5	7
429	Antibacterial and anti-inflammatory activity of a temporin B peptide analogue on an <i>in vitro</i> model of cystic fibrosis. Journal of Peptide Science, 2014, 20, 822-830.	1.4	27
430	The draft genome sequence of the ferret (Mustela putorius furo) facilitates study of human respiratory disease. Nature Biotechnology, 2014, 32, 1250-1255.	17.5	110
431	Expression of microRNA-93 and Interleukin-8 during <i>Pseudomonas aeruginosa</i> –Mediated Induction of Proinflammatory Responses. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 1144-1155.	2.9	82
432	Cytosolic phospholipase A2α enhances mouse mortality induced by Pseudomonas aeruginosa pulmonary infection via interleukin 6. Biochimie, 2014, 107, 95-104.	2.6	24
433	Current concepts: host-pathogen interactions in cystic fibrosis airways disease. European Respiratory Review, 2014, 23, 320-332.	7.1	55
434	Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis. European Respiratory Journal, 2014, 43, 610-626.	6.7	23
435	Infliximab is safe and induces sustained remission with complete mucosal healing in Crohn's disease in a patient with pan resistant pseudomonas cystic fibrosis: A case report. Journal of Crohn's and Colitis, 2014, 8, 1561-1562.	1.3	3
436	A novel Pseudomonas aeruginosa-derived effector cooperates with flagella to mediate the upregulation of interleukin 8 in human epithelial cells. Microbial Pathogenesis, 2014, 66, 24-28.	2.9	13
437	Lung disease modifier genes in cystic fibrosis. International Journal of Biochemistry and Cell Biology, 2014, 52, 83-93.	2.8	66
438	Vaccinating High-Risk Children with the Intranasal Live-Attenuated Influenza Vaccine: the Quebec Experience. Paediatric Respiratory Reviews, 2014, 15, 340-347.	1.8	6
439	Asthma and cystic fibrosis: A tangled web. Pediatric Pulmonology, 2014, 49, 205-213.	2.0	33
440	Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis. Pediatrics, 2014, 134, e983-e991.	2.1	14
441	The cystic fibrosis gender gap: Potential roles of estrogen. Pediatric Pulmonology, 2014, 49, 309-317.	2.0	49
442	Translational Research in Pediatrics III: Bronchoalveolar Lavage. Pediatrics, 2014, 134, 135-154.	2.1	25
443	Inhibition of co-colonizing cystic fibrosis-associated pathogens by Pseudomonas aeruginosa and Burkholderia multivorans. Microbiology (United Kingdom), 2014, 160, 1474-1487.	1.8	33
444	Mechanisms of phagocytosis and host clearance of <i>Pseudomonas aeruginosa</i> . American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L591-L603.	2.9	141

#	Article	IF	CITATIONS
445	Mesoscopic modeling as a starting point for computational analyses of cystic fibrosis as a systemic disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 258-270.	2.3	21
446	Inflammation and its genesis in cystic fibrosis. Pediatric Pulmonology, 2015, 50, S39-56.	2.0	148
447	Symposium Summaries. Pediatric Pulmonology, 2015, 50, S108-S192.	2.0	1
448	CFTR Knockdown induces proinflammatory changes in intestinal epithelial cells. Journal of Inflammation, 2015, 12, 62.	3.4	30
449	Downâ€regulation of <scp>IL</scp> â€8 by highâ€dose vitamin <scp>D</scp> is specific to hyperinflammatory macrophages and involves mechanisms beyond upâ€regulation of <scp><i>DUSP1</i></scp> . British Journal of Pharmacology, 2015, 172, 4757-4771.	5.4	52
450	Epithelium-Specific Ets-Like Transcription Factor 1, ESE-1, Regulates ICAM-1 Expression in Cultured Lung Epithelial Cell Lines. Mediators of Inflammation, 2015, 2015, 1-8.	3.0	6
451	Transcription of Interleukin-8: How Altered Regulation Can Affect Cystic Fibrosis Lung Disease. Biomolecules, 2015, 5, 1386-1398.	4.0	99
452	Role of Non-coding RNAs in Cystic Fibrosis. , 2015, , .		2
453	Angiotensin-Converting Enzyme 2 Attenuates Bleomycin-Induced Lung Fibrosis in Mice. Cellular Physiology and Biochemistry, 2015, 36, 697-711.	1.6	47
454	CFTR regulates acute inflammatory responses in macrophages. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 951-958.	0.5	17
455	Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1407-1409.	5.6	43
456	Macrophage Dysfunction in Cystic Fibrosis: A Therapeutic Target to Enhance Self-Immunity. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1406-1407.	5.6	10
457	Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. Journal of Cystic Fibrosis, 2015, 14, 228-236.	0.7	36
458	Glucocorticoids can affectPseudomonas aeruginosa(ATCC 27853) internalization and intracellular calcium concentration in cystic fibrosis bronchial epithelial cells. Experimental Lung Research, 2015, 41, 383-392.	1.2	3
459	Psoralen derivatives as inhibitors of NF- \$\$upkappa hbox {B/DNA}\$\$ κ B/DNA interaction: the critical role of the furan ring. Molecular Diversity, 2015, 19, 551-561.	3.9	6
460	Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis. Nature Communications, 2015, 6, 6201.	12.8	130
461	SERCA and PMCA pumps contribute to the deregulation of Ca2+ homeostasis in human CF epithelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 892-903.	4.1	21
462	Residence in biofilms allows <i>Burkholderia cepacia</i> complex (Bcc) bacteria to evade the anti-microbial activities of neutrophil-like dHL60 cells. Pathogens and Disease, 2015, 73, ftv069.	2.0	12

#	Article	IF	CITATIONS
463	X-Box–Binding Protein 1 and Innate Immune Responses of Human Cystic Fibrosis Alveolar Macrophages. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1449-1461.	5.6	57
464	Pulmonary macrophages: key players in the innate defence of the airways. Thorax, 2015, 70, 1189-1196.	5.6	359
465	Phloridzin derivatives inhibiting pro-inflammatory cytokine expression in human cystic fibrosis IB3-1 cells. European Journal of Pharmaceutical Sciences, 2015, 78, 225-233.	4.0	10
466	The Tyrosine Kinase BceF and the Phosphotyrosine Phosphatase BceD of Burkholderia contaminans Are Required for Efficient Invasion and Epithelial Disruption of a Cystic Fibrosis Lung Epithelial Cell Line. Infection and Immunity, 2015, 83, 812-821.	2.2	18
467	Antiinflammatory and Antimicrobial Effects of Thiocyanate in a Cystic Fibrosis Mouse Model. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 193-205.	2.9	51
468	Cystic fibrosis airway epithelium remodelling: involvement of inflammation. Journal of Pathology, 2015, 235, 408-419.	4.5	57
469	Autophagy in Cystic Fibrosis Pathogenesis and Treatment. , 0, , .		1
470	Epithelial Anion Transport as Modulator of Chemokine Signaling. Mediators of Inflammation, 2016, 2016, 1-20.	3.0	10
471	Role of Cytokine-Induced Glycosylation Changes in Regulating Cell Interactions and Cell Signaling in Inflammatory Diseases and Cancer. Cells, 2016, 5, 43.	4.1	60
472	Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease. PLoS Pathogens, 2016, 12, e1005846.	4.7	170
473	Cystic Fibrosis Lung Immunity: The Role of the Macrophage. Journal of Innate Immunity, 2016, 8, 550-563.	3.8	141
474	Neutrophils from F508del cystic fibrosis patients produce IL-17A and express IL-23 - dependent IL-17RC. Clinical Immunology, 2016, 170, 53-60.	3.2	27
475	Aspergillus infections in cystic fibrosis. Journal of Infection, 2016, 72, S50-S55.	3.3	65
476	Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1459-1471.	3.8	38
477	Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms. Epigenomics, 2016, 8, 1087-1101.	2.1	23
478	Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings. Open Forum Infectious Diseases, 2016, 3, ofw187.	0.9	3
479	Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseases. Journal of Drug Targeting, 2016, 24, 805-820.	4.4	9
480	Endoplasmic reticulum stress regulates chemokine production in cystic fibrosis airway cells through STAT3 modulation. Journal of Infectious Diseases, 2017, 215, jiw516.	4.0	25

#	Article	IF	CITATIONS
481	Biochemical and Cellular Characterization and Inhibitor Discovery of <i>Pseudomonas aeruginosa</i> 15-Lipoxygenase. Biochemistry, 2016, 55, 3329-3340.	2.5	39
482	Transient Receptor Potential Ankyrin 1 Channels Modulate Inflammatory Response in Respiratory Cells from Patients with Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 645-656.	2.9	34
483	Acute toxicity of silver and carbon nanoaerosols to normal and cystic fibrosis human bronchial epithelial cells. Nanotoxicology, 2016, 10, 279-291.	3.0	38
484	Airway Epithelium and Mucous Secretion. , 2016, , 157-167.e3.		0
485	Prevalidation of the ex-vivo model PCLS for prediction of respiratory toxicity. Toxicology in Vitro, 2016, 32, 347-361.	2.4	33
486	Innate and Adaptive Immunity in Cystic Fibrosis. Clinics in Chest Medicine, 2016, 37, 17-29.	2.1	73
487	Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgraduate Medicine, 2017, 129, 493-499.	2.0	69
488	An antisense peptide nucleic acid against Pseudomonas aeruginosa inhibiting bacterial-induced inflammatory responses in the cystic fibrosis IB3-1 cellular model system. International Journal of Biological Macromolecules, 2017, 99, 492-498.	7.5	19
489	Macrophages. Results and Problems in Cell Differentiation, 2017, , .	0.7	8
490	Macrophage Dysfunction in Respiratory Disease. Results and Problems in Cell Differentiation, 2017, 62, 299-313.	0.7	68
491	Membrane translocation of transient receptor potential ankyrin 1 induced by inflammatory cytokines in lung cancer cells. Biochemical and Biophysical Research Communications, 2017, 490, 587-593.	2.1	12
492	Monocyte derived macrophages from CF pigs exhibit increased inflammatory responses at birth. Journal of Cystic Fibrosis, 2017, 16, 471-474.	0.7	35
493	Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo. Cytokine, 2017, 91, 65-73.	3.2	32
494	Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia. Scientific Reports, 2017, 7, 14388.	3.3	36
495	The impact of impaired macrophage functions in cystic fibrosis disease progression. Journal of Cystic Fibrosis, 2017, 16, 443-453.	0.7	69
496	Regulation of <scp>mRNA</scp> turnover in cystic fibrosis lung disease. Wiley Interdisciplinary Reviews RNA, 2017, 8, e1408.	6.4	1
497	Bacterial proteases and haemostasis dysregulation in the CF lung. Journal of Cystic Fibrosis, 2017, 16, 49-57.	0.7	3
498	Airway inflammation in mild cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 107-115.	0.7	24

#	Article	IF	CITATIONS
499	The burgeoning field of innate immuneâ€mediated disease and autoinflammation. Journal of Pathology, 2017, 241, 123-139.	4.5	62
500	Septic cardiomyopathy: evidence for a reduced force-generating capacity of human atrial myocardium in acute infective endocarditis. Innovative Surgical Sciences, 2017, 2, 81-87.	0.7	2
501	β-Sitosterol Reduces the Expression of Chemotactic Cytokine Genes in Cystic Fibrosis Bronchial Epithelial Cells. Frontiers in Pharmacology, 2017, 8, 236.	3.5	32
502	Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation. International Journal of Molecular Sciences, 2017, 18, 118.	4.1	32
503	The anti-microbial peptide TP359 attenuates inflammation in human lung cells infected with Pseudomonas aeruginosa via TLR5 and MAPK pathways. PLoS ONE, 2017, 12, e0176640.	2.5	21
504	Effects of coconut oil on glycemia, inflammation, and urogenital microbial parameters in female Ossabaw mini-pigs. PLoS ONE, 2017, 12, e0179542.	2.5	14
505	Biomarkers of Inflammation and Remodelling in Cystic Fibrosis. Clinical Immunology, Endocrine and Metabolic Drugs, 2017, 3, .	0.3	3
506	PLCB3 Loss of Function Reduces <i>Pseudomonas aeruginosa</i> –Dependent IL-8 Release in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 428-436.	2.9	15
507	Sphingolipids as targets for inhalation treatment of cystic fibrosis. Advanced Drug Delivery Reviews, 2018, 133, 66-75.	13.7	25
508	TGFβ as a therapeutic target in cystic fibrosis. Expert Opinion on Therapeutic Targets, 2018, 22, 177-189.	3.4	36
509	Mucin Production and Hydration Responses to Mucopurulent Materials in Normal versus Cystic Fibrosis Airway Epithelia. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 481-491.	5.6	38
510	A slippery slope: On the origin, role and physiology of mucus. Advanced Drug Delivery Reviews, 2018, 124, 16-33.	13.7	130
511	Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia. Frontiers in Immunology, 2018, 9, 2943.	4.8	35
512	Genome-wide DNA methylation profiling shows a distinct epigenetic signature associated with lung macrophages in cystic fibrosis. Clinical Epigenetics, 2018, 10, 152.	4.1	28
513	Lung Diseases. Experientia Supplementum (2012), 2018, 108, 61-84.	0.9	3
514	Guanylate binding proteins facilitate caspase-11-dependent pyroptosis in response to type 3 secretion system-negative Pseudomonas aeruginosa. Cell Death Discovery, 2018, 4, 3.	4.7	51
515	Inflammation in cystic fibrosis: An update. Pediatric Pulmonology, 2018, 53, S30-S50.	2.0	187
516	The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease. Expert Opinion on Therapeutic Targets, 2018, 22, 687-701.	3.4	57

#	Article	IF	CITATIONS
517	Kcnn4 is a modifier gene of intestinal cystic fibrosis preventing lethality in the Cftr-F508del mouse. Scientific Reports, 2018, 8, 9320.	3.3	14
518	Pulmonary Disease in Cystic Fibrosis. , 2019, , 777-787.e4.		4
519	Reducing the frequency of respiratory tract infections in severe neurological disorders by inhaled antibiotics: a retrospective data analysis. ERJ Open Research, 2019, 5, 00149-2018.	2.6	9
520	Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1α Arm of the Unfolded Protein Response Results in Exacerbated Inflammation. Frontiers in Immunology, 2019, 10, 1789.	4.8	41
521	Current Practices and Potential Nanotechnology Perspectives for Pain Related to Cystic Fibrosis. Journal of Clinical Medicine, 2019, 8, 1023.	2.4	7
522	Antiâ€inflammatories and mucociliary clearance therapies in the age of CFTR modulators. Pediatric Pulmonology, 2019, 54, S46-S55.	2.0	18
523	Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1381-1391.	5.6	74
524	Characterization of cystic fibrosis airway smooth muscle cell proliferative and contractile activities. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L690-L701.	2.9	6
525	Microbial uptake by the respiratory epithelium: outcomes for host and pathogen. FEMS Microbiology Reviews, 2019, 43, 145-161.	8.6	24
526	Microbiology of the Cystic Fibrosis Airway. , 2019, , .		2
526 527	Microbiology of the Cystic Fibrosis Airway. , 2019, , . Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clinical Microbiology Reviews, 2019, 32, .	13.6	2 264
526 527 528	Microbiology of the Cystic Fibrosis Airway. , 2019, , . Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clinical Microbiology Reviews, 2019, 32, . Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88.	13.6	2 264 8
526 527 528 529	Microbiology of the Cystic Fibrosis Airway., 2019, , . Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clinical Microbiology Reviews, 2019, 32, . Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88. Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. Journal of Cystic Fibrosis, 2019, 18, 796-803.	13.6 3.1 0.7	2 264 8 36
526 527 528 529	Microbiology of the Cystic Fibrosis Airway. , 2019, , . Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clinical Microbiology Reviews, 2019, 32, . Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88. Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. Journal of Cystic Fibrosis, 2019, 18, 796-803. Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Frontiers in Pharmacology, 2019, 10, 252.	13.6 3.1 0.7 3.5	2 264 8 36 40
526 527 528 529 530	Microbiology of the Cystic Fibrosis Airway., 2019, , . Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clinical Microbiology Reviews, 2019, 32, . Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88. Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. Journal of Cystic Fibrosis, 2019, 18, 796-803. Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Frontiers in Pharmacology, 2019, 10, 252. Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the ILâ€4 signaling pathway. Pediatric Pulmonology, 2019, 54, S5-S12.	13.6 3.1 0.7 3.5 2.0	2 264 8 36 40 48
 526 527 528 529 530 531 532 	Microbiology of the Cystic Fibrosis Airway. , 2019, , . Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clinical Microbiology Reviews, 2019, 32, . Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88. Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. Journal of Cystic Fibrosis, 2019, 18, 796-803. Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Frontiers in Pharmacology, 2019, 10, 252. Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the ILâ€4 signaling pathway. Pediatric Pulmonology, 2019, 54, S5-S12. High Nuclease Activity of Long Persisting Staphylococcus aureus Isolates Within the Airways of Cystic Fibrosis Patients Protects Against NET-Mediated Killing. Frontiers in Immunology, 2019, 10, 2552.	13.6 3.1 0.7 3.5 2.0 4.8	2 264 8 36 40 48
 526 527 528 529 530 531 532 533 	Microbiology of the Cystic Fibrosis Airway., 2019, , . Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clinical Microbiology Reviews, 2019, 32, . Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88. Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. Journal of Cystic Fibrosis, 2019, 18, 796-803. Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Frontiers in Pharmacology, 2019, 10, 252. Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the ILAEA signaling pathway. Pediatric Pulmonology, 2019, 54, S5-S12. High Nuclease Activity of Long Persisting Staphylococcus aureus Isolates Within the Airways of Cystic Fibrosis Patients Protects Against NET-Mediated Killing. Frontiers in Immunology, 2019, 10, 2552. Novel Application of Aptamer Proteomic Analysis in Cystic Fibrosis Bronchoalveolar Lavage Fluid. Proteomics - Clinical Applications, 2019, 13, e1800085.	13.6 3.1 0.7 3.5 2.0 4.8	2 264 8 36 40 48 37

#	Article	IF	CITATIONS
535	TNFα â^'857â€⁻C/T and TNFR2 +587ÂT/G polymorphisms are associated with cystic fibrosis in Iranian patients. European Journal of Medical Genetics, 2019, 62, 103584.	1.3	10
536	ncRNAs in Inflammatory and Infectious Diseases. Methods in Molecular Biology, 2019, 1912, 3-32.	0.9	18
537	Development of a vaccine against <i>Staphylococcus aureus</i> invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms. FEMS Microbiology Reviews, 2020, 44, 123-153.	8.6	138
538	Immune dysregulation increases the incidence of delayedâ€ŧype drug hypersensitivity reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 781-797.	5.7	21
539	Intracellular survival and innate immune evasion of <i>Burkholderia cepacia</i> : Improved understanding of quorum sensingâ€controlled virulence factors, biofilm, and inhibitors. Microbiology and Immunology, 2020, 64, 87-98.	1.4	17
540	The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 414-429.	2.5	12
541	Alkaloids of Abuta panurensis Eichler: In silico and in vitro study of acetylcholinesterase inhibition, cytotoxic and immunomodulatory activities. PLoS ONE, 2020, 15, e0239364.	2.5	6
542	The Role of Specialized Pro-Resolving Mediators in Cystic Fibrosis Airways Disease. Frontiers in Pharmacology, 2020, 11, 1290.	3.5	11
543	An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 121-130.	4.3	15
544	Autophagy markers as mediators of lung injury-implication for therapeutic intervention. Life Sciences, 2020, 260, 118308.	4.3	40
545	Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis. Frontiers in Pharmacology, 2020, 11, 1059.	3.5	22
546	Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, 200-210.	4.3	27
547	Th17 associated cytokines in sputum samples from patients with cystic fibrosis. Pathogens and Disease, 2020, 78, .	2.0	5
548	Caspase-11 Non-canonical Inflammasomes in the Lung. Frontiers in Immunology, 2020, 11, 1895.	4.8	18
549	Airway Inflammation and Host Responses in the Era of CFTR Modulators. International Journal of Molecular Sciences, 2020, 21, 6379.	4.1	36
550	Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. Microorganisms, 2020, 8, 1704.	3.6	37
551	Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations. Cellular and Molecular Life Sciences, 2020, 77, 4485-4503.	5.4	42
552	Resolvin D1 Reduces Lung Infection and Inflammation Activating Resolution in Cystic Fibrosis. Frontiers in Immunology, 2020, 11, 581.	4.8	56

#	Article	IF	CITATIONS
553	LncRNA GAS5 attenuates fibroblast activation through inhibiting Smad3 signaling. American Journal of Physiology - Cell Physiology, 2020, 319, C105-C115.	4.6	27
554	The role of inflammation in cystic fibrosis pulmonary exacerbations. Expert Review of Respiratory Medicine, 2020, 14, 889-903.	2.5	3
555	Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic Infections. Frontiers in Immunology, 2020, 11, 244.	4.8	68
556	Neutrophil extracellular traps activate IL-8 and IL-1 expression in human bronchial epithelia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L137-L147.	2.9	42
557	Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1133-1145.	5.6	26
558	Targeting defective pulmonary innate immunity – A new therapeutic option?. , 2020, 209, 107500.		26
559	Levels of pro- and anti-inflammatory cytokines in cystic fibrosis patients with or without gingivitis. Cytokine, 2020, 127, 154987.	3.2	7
560	Enhanced inflammasome activation and reduced sphingosine-1 phosphate S1P signalling in a respiratory mucoobstructive disease model. Journal of Inflammation, 2020, 17, 16.	3.4	6
561	Novel Immunomodulatory Therapies for Respiratory Pathologies. , 2022, , 554-594.		5
562	The journey of SARS-CoV-2 in human hosts: a review of immune responses, immunosuppression, and their consequences. Virulence, 2021, 12, 1771-1794.	4.4	18
563	Impairment in inflammasome signaling by the chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients results in an increase in inflammatory response. Cell Death and Disease, 2021, 12, 241.	6.3	8
564	SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. Microorganisms, 2021, 9, 525.	3.6	30
565	Resolvin D1 and D2 reduce SARSâ€CoVâ€2â€induced inflammatory responses in cystic fibrosis macrophages. FASEB Journal, 2021, 35, e21441.	0.5	42
566	Cytokine signaling pathway in cystic fibrosis: expression of SOCS and STATs genes in different clinical phenotypes of the disease. Molecular and Cellular Biochemistry, 2021, 476, 2869-2876.	3.1	7
567	Lipopolysaccharide from biofilm-forming Pseudomonas aeruginosa PAO1 induces macrophage hyperinflammatory responses. Journal of Medical Microbiology, 2021, 70, .	1.8	10
568	Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine. Genes, 2021, 12, 562.	2.4	21
569	Inflammasome Genetic Variants, Macrophage Function, and Clinical Outcomes in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 157-166.	2.9	11
570	Cardiovascular complications in cystic fibrosis: A review of the literature. Journal of Cystic Fibrosis, 2022, 21, 18-25.	0.7	25

#	Article	IF	Citations
571	Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6. Clinical and Experimental Immunology, 2021, 205, 391-405.	2.6	5
572	Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis. Antibiotics, 2021, 10, 1043.	3.7	2
573	Serum inflammatory profiles in cystic fibrosis mice with and without Bordetella pseudohinzii infection. Scientific Reports, 2021, 11, 17535.	3.3	8
574	Aspiration, Bronchial Obstruction, Bronchiectasis, and Related Disorders. , 2008, , 84-131.		4
575	The Glycosylation of Airway Mucins in Cystic Fibrosis and its Relationship with Lung Infection by Pseudomonas aeruginosa. Advances in Experimental Medicine and Biology, 2003, 535, 17-32.	1.6	29
576	Pseudomonas Aeruginosa Infections in Individuals with Cystic Fibrosis. Perspectives on Critical Care Infectious Diseases, 2003, , 71-89.	0.1	3
577	Methods for Evaluating Inflammation in Cystic Fibrosis. Methods in Molecular Biology, 2011, 742, 51-76.	0.9	1
578	Serine and Cysteine Proteases and Their Inhibitors as Antimicrobial Agents and Immune Modulators. , 2011, , 27-50.		4
579	Contribution of endothelial cells to airway inflammation. , 2000, , 223-244.		3
580	Diagnostik der cystischen Fibrose. , 2001, , 185-253.		1
581	Pulmonary Disease in Cystic Fibrosis. , 2006, , 873-886.		4
583	Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. European Respiratory Journal, 1999, 14, 339-346.	6.7	74
584	Lung inflammatory responses. Veterinary Research, 2006, 37, 469-486.	3.0	59
585	Aerosolized antibiotics in mechanically ventilated patients. Critical Care Medicine, 1998, 26, 31-39.	0.9	169
588	Pseudomonas aeruginosa Infections. , 0, , 305-326.		8
589	Cytokines and Inflammatory Mediators Do Not Indicate Acute Infection in Cystic Fibrosis. Vaccine Journal, 1999, 6, 260-265.	2.6	41
590	Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infection and Immunity, 1996, 64, 4984-4992.	2.2	66
591	Altered cytokine production by cystic fibrosis tracheal gland serous cells. Infection and Immunity, 1997, 65, 5176-5183.	2.2	56

#	Article	IF	CITATIONS
592	Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infection and Immunity, 1997, 65, 3838-3846.	2.2	241
593	Microbial Pathogenesis in Cystic Fibrosis: Pulmonary Clearance of Mucoid <i>Pseudomonas aeruginosa</i> and Inflammation in a Mouse Model of Repeated Respiratory Challenge. Infection and Immunity, 1998, 66, 280-288.	2.2	74
594	Interleukin-4 Enhances Pulmonary Clearance of <i>Pseudomonas aeruginosa</i> . Infection and Immunity, 1998, 66, 4229-4236.	2.2	52
595	<i>Pseudomonas aeruginosa</i> Quorum-Sensing Signal Molecule <i>N</i> -(3-Oxododecanoyl)- <scp> </scp> -Homoserine Lactone Inhibits Expression of P2Y Receptors in Cystic Fibrosis Tracheal Gland Cells. Infection and Immunity, 1999, 67, 5076-5082.	2.2	49
596	Acidosis exacerbates in vivo IL-1-dependent inflammatory responses and neutrophil recruitment during pulmonary <i>Pseudomonas aeruginosa</i> infection. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L225-L235.	2.9	21
597	CCL20 Is an Inducible Product of Human Airway Epithelia with Innate Immune Properties. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 627-633.	2.9	113
598	Airway epithelial homeostasis and planar cell polarity signaling depend on multiciliated cell differentiation. JCI Insight, 2016, 1, .	5.0	63
599	Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. Journal of Clinical Investigation, 2002, 109, 661-670.	8.2	300
600	IL-1β dominates the promucin secretory cytokine profile in cystic fibrosis. Journal of Clinical Investigation, 2019, 129, 4433-4450.	8.2	91
601	Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. Journal of Clinical Investigation, 2002, 109, 661-670.	8.2	184
602	Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells Journal of Clinical Investigation, 1998, 101, 2598-2605.	8.2	280
604	Evidence of Chronic Inflammation in Morphologically Normal Small Intestine of Cystic Fibrosis Patients. Pediatric Research, 2000, 47, 344-350.	2.3	97
605	Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis. Drug News and Perspectives, 2006, 19, 609.	1.5	47
606	Elevated IgG4 serum levels in patients with cystic fibrosis. PLoS ONE, 2017, 12, e0181888.	2.5	13
607	Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target. Current Drug Targets, 2016, 17, 1535-1544.	2.1	20
608	Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. Open Respiratory Medicine Journal, 2010, 4, 32-38.	0.4	26
609	Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation~!2009-08-07~!2009-11-10~!2010-03-30~!. Open Respiratory Medicine Journal, 2010, 4, 32-38.	0.4	26
610	Airway-Clearance Therapy Guidelines and Implementation. Respiratory Care, 2009, 54, 733-753.	1.6	49

#	Article	IF	CITATIONS
611	Exhaled Breath Condensates as a Source for Biomarkers for Characterization of Inflammatory Lung Diseases. Journal of Analytical Sciences Methods and Instrumentation, 2013, 03, 17-29.	0.1	10
612	Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease. Stem Cell Discovery, 2013, 03, 139-153.	0.5	28
613	Review on Recent Aspects of Biochemical, Cellular, Physiological Markers and Environmental Factors Associated with Acute Lung Inflammation & Injury (ALI). American Journal of Biochemistry, 2012, 2, 74-88.	0.3	1
614	Mapping Pulmonary and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis. Frontiers in Immunology, 2021, 12, 733217.	4.8	8
616	Abwehrsysteme. , 2001, , 121-184.		0
617	IL-10 Controls Aspergillus fumigatus??? and Pseudomonas aeruginosa???Specific T-Cell Response in Cystic Fibrosis. Pediatric Research, 2003, 53, 313-319.	2.3	17
618	Oxidative and Nitrosative Stress in Cystic Fibrosis. Oxidative Stress and Disease, 2003, , .	0.3	0
619	Bronchoalveolar Lavage in Interstitial Lung Disease. Lung Biology in Health and Disease, 2003, , 253-272.	0.1	0
620	Neutrophil Elastase (NE) and NE Inhibitors: Canonical and Noncanonical Functions in Lung Chronic Inflammatory Diseases (Cystic Fibrosis and Chronic Obstructive Pulmonary Disease). Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
621	Antiproteases as Therapeutics to Target Inflammation in Cystic Fibrosis–!2009-07-21~!2009-10-30~!2010-03-30~!. Open Respiratory Medicine Journal, 2010, 4, 20-31.	0.4	23
622	A polymorphism in ADRB2 gene is associated with severity of pulmonary phenotype in Cystic Fibrosis patients Genetics of Multifactorial Disorders, 2014, 1, .	0.0	0
624	Clinical Outcomes Associated with Interleukin 6 and Interleukin 8 Cytokine Production in Cystic Fibrosis. British Journal of Medicine and Medical Research, 2015, 6, 164-172.	0.2	2
625	Pseudomonas Quinolone Signal Modulates Cystic Fibrosis Epithelial Cell Response through the Toll- Like Receptor 4. SOJ Immunology, 2015, 3, .	0.2	0
627	Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages. European Respiratory Journal, 2021, 57, 2003502.	6.7	17
628	The Interplay between the Unfolded Protein Response, Inflammation and Infection in Cystic Fibrosis. Cells, 2021, 10, 2980.	4.1	12
629	Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis. Expert Review of Respiratory Medicine, 2022, 16, 43-56.	2.5	5
637	Cystic fibrosis therapywhere we are and how we got there. Western Journal of Medicine, 1996, 164, 361-2.	0.3	2
638	Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress. Clinical Biochemist Reviews, 2009, 30, 153-77.	3.3	42

#	Article	IF	Citations
639	A STUDY OF THE ANTI-INFLAMMATORY EFFECTS OF THE ETHYL ACETATE FRACTION OF THE METHANOL EXTRACT OF FORSYTHIAE FRUCTUS. African Journal of Traditional Complementary and Alternative Medicines. 2016. 13, 102-113	0.2	2
641	Pseudomonas aeruginosa modulates alginate biosynthesis and type VI secretion system in two critically ill COVID-19 patients. Cell and Bioscience, 2022, 12, 14.	4.8	8
642	Macrophages in respiratory system. , 2022, , 299-333.		0
643	Xylitol as a Hydrophilization Moiety for a Biocatalytically Synthesized Ibuprofen Prodrug. International Journal of Molecular Sciences, 2022, 23, 2026.	4.1	7
645	<i>Pseudomonas aeruginosa</i> polysaccharide Psl supports airway microbial community development. ISME Journal, 2022, 16, 1730-1739.	9.8	18
646	Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine. Journal of Clinical Medicine, 2021, 10, 5821.	2.4	16
647	Immunoglobulin A Mucosal Immunity and Altered Respiratory Epithelium in Cystic Fibrosis. Cells, 2021, 10, 3603.	4.1	9
655	A STUDY OF THE ANTI-INFLAMMATORY EFFECTS OF THE ETHYL ACETATE FRACTION OF THE METHANOL EXTRACT OF FORSYTHIAE FRUCTUS. Tropical Journal of Obstetrics and Gynaecology, 2016, 13, 102-113.	0.3	6
656	Changes in Microbiome Dominance Are Associated With Declining Lung Function and Fluctuating Inflammation in People With Cystic Fibrosis. Frontiers in Microbiology, 2022, 13, .	3.5	6
658	CF-Seq, an accessible web application for rapid re-analysis of cystic fibrosis pathogen RNA sequencing studies. Scientific Data, 2022, 9, .	5.3	7
659	LONG-TERM USE OF INHALED HYPERTONIC SALINE IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS: EXPERIENCE FROM A TERTIARY CARE CENTER IN A LOW AND MIDDLE INCOME COUNTRY. Journal of Ayub Medical College, Abbottabad: JAMC, 2022, 34, .	0.1	0
660	Distinct fates of monocytes and T cells directly activated by <i>Pseudomonas aeruginosa</i> exoenzyme S. Journal of Leukocyte Biology, 2002, 71, 458-468.	3.3	18
661	Modulating macrophage function to reinforce host innate resistance against Mycobacterium avium complex infection. Frontiers in Immunology, 0, 13, .	4.8	4
662	Resident macrophages of the lung and liver: The guardians of our tissues. Frontiers in Immunology, 0, 13, .	4.8	6
664	NLRP3 inflammasome as a novel target for cystic fibrosis treatment. Bulletin of the National Research Centre, 2023, 47, .	1.8	1
665	Competitive survival of clonal serial Pseudomonas aeruginosa isolates from cystic fibrosis airways in human neutrophils. IScience, 2023, 26, 106475.	4.1	1
666	Sex-biased expression of selected chromosome x-linked microRNAs with potent regulatory effect on the inflammatory response in children with cystic fibrosis: A preliminary pilot investigation. Frontiers in Immunology, 0, 14, .	4.8	3
667	Control of mitochondrial functions by Pseudomonas aeruginosa in cystic fibrosis. International Review of Cell and Molecular Biology, 2023, , .	3.2	1

#	Article	IF	CITATIONS
668	Furin as a therapeutic target in cystic fibrosis airways disease. European Respiratory Review, 2023, 32, 220256.	7.1	1
669	CACE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages. Science Advances, 2023, 9, .	10.3	3
670	A novel in vitro model to study prolonged Pseudomonas aeruginosa infection in the cystic fibrosis bronchial epithelium. PLoS ONE, 2023, 18, e0288002.	2.5	2
671	EEF2-inactivating toxins engage the NLRP1 inflammasome and promote epithelial barrier disruption. Journal of Experimental Medicine, 2023, 220, .	8.5	4
672	Fibroblast Growth Factor 23 Signaling Does Not Increase Inflammation from Pseudomonas aeruginosa Infection in the Cystic Fibrosis Bronchial Epithelium. Medicina (Lithuania), 2023, 59, 1635.	2.0	1
674	A Novel Co-Culture Model Reveals Enhanced CFTR Rescue in Primary Cystic Fibrosis Airway Epithelial Cultures with Persistent Pseudomonas aeruginosa Infection. Cells, 2023, 12, 2618.	4.1	0
675	Plasma levels of chemokines decrease during elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis. Heliyon, 2024, 10, e23428.	3.2	0
676	Gene Modifiers in Pediatrics: Application to Cystic Fibrosis. Advances in Pediatrics, 2004, 51, 5-36.	1.4	0
677	Heterogeneity in Neutrophil Extracellular Traps from Healthy Human Subjects. International Journal of Molecular Sciences, 2024, 25, 525.	4.1	0